Evidence map›Paper›PMID 40108169›Full record

ArticleNature communications2025

Orally delivered toxin-binding protein protects against diarrhoea in a murine cholera model.

Marcus Petersson, Franz G Zingl, Everardo Rodriguez-Rodriguez, Jakob K H Rendsvig, Heidi Heinsøe, Emma Wenzel Arendrup, Natalia Mojica, Dario Segura Peña, Nikolina Sekulić, Ute Krengel and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Marcus Petersson *Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID http://orcid.org/0000-0002-2466-9038
Franz G Zingl *Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0874-4234
Everardo Rodriguez-RodriguezBactolife A/S, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-7445-2830
Jakob K H RendsvigBactolife A/S, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-4603-9424
Heidi HeinsøeBactolife A/S, Copenhagen, Denmark.
Emma Wenzel ArendrupBactolife A/S, Copenhagen, Denmark.ORCID http://orcid.org/0009-0006-5709-9322
Natalia MojicaDepartment of Chemistry, University of Oslo, Oslo, Norway.
Dario Segura PeñaCentre for Molecular Medicine Norway, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0001-6695-1042
Nikolina SekulićCentre for Molecular Medicine Norway, University of Oslo, Oslo, Norway.
Ute KrengelDepartment of Chemistry, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0001-6688-8151
Monica L Fernández-QuinteroDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
Timothy P JenkinsDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID http://orcid.org/0000-0003-2979-5663
Lone GramDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID http://orcid.org/0000-0002-1076-5723
Matthew K WaldorDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1843-7000
Andreas H LaustsenDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark. ahola@bio.dtu.dk.ORCID http://orcid.org/0000-0001-6918-5574
Sandra Wingaard ThraneBactolife A/S, Copenhagen, Denmark. swt@bactolife.com.ORCID http://orcid.org/0000-0003-2098-2710

Funding

Vibrio cholerae intestinal colonization and vaccine developmentR01AI042347 · NIAID · TUFTS UNIVERSITY BOSTON · PI WALDOR, MATTHEW K · 1998 to 2025
$7.3M
Innovationsfonden (Innovation Fund Denmark) 1044-00106BLife Sciences Research Foundation (LSRF) Zingl-2024HHMINIAID NIH HHS R01 AI042347U.S. Department of Health & Human Services | National Institutes of Health (NIH) NIH R01 AI042347
6 · The paper itself

Abstract

The ongoing seventh cholera pandemic, which began in 1961, poses an escalating threat to public health. There is a need for new cholera control measures, particularly ones that can be produced at low cost, for the one billion people living in cholera-endemic regions. Orally delivered V

Indexed as

CholeraCholera ToxinCholera VaccinesDiarrheaAdministration, OralAnimalsDisease Models, AnimalFemaleHumansMiceVibrio choleraeCholera ToxinCholera Vaccines

Identifiers

PMID40108169
PMCPMC11923127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.